A new combined predicting model using a non-invasive score for the assessment of liver fibrosis in patients presenting with chronic hepatitis B virus infection.

•Histological staging of liver fibrosis is a crucial step to identify the therapeutic strategy in patients presenting with chronic hepatitis B infection.•Several non-invasive scores have recently been validated to assess liver fibrosis.•These scores are of major interest, as they may accurately predict liver fibrosis without percutaneous liver biopsy.•This is the first study that combined two biological non-invasive scores (APRI and FIB-4) in predicting liver fibrosis in patients presenting with chronic hepatitis B infection.•We proposed a useful stepwise algorithm in chronic hepatitis B infection management to select patients who really need percutaneous liver biopsy.